Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
Study Number: 

NCG 275215-Z1E

Phase: 
2
Principal Investigator: